SomnoMed Limited, headquartered in Australia, is a leading innovator in the field of sleep medicine, specialising in the development of oral appliances for the treatment of obstructive sleep apnoea (OSA). Founded in 2004, the company has established a strong presence in key markets across North America, Europe, and Asia-Pacific, positioning itself as a trusted name in sleep therapy solutions. SomnoMed's flagship products, including the SomnoDent range, are distinguished by their patient-centric design and customisation options, ensuring comfort and efficacy. The company has achieved significant milestones, including regulatory approvals and partnerships with dental professionals, solidifying its market position as a pioneer in non-invasive sleep treatment. With a commitment to improving patient outcomes, SomnoMed continues to lead the way in advancing sleep health solutions globally.
How does SomnoMed Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
SomnoMed Limited's score of 11 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SomnoMed Limited, headquartered in Australia, currently does not have any available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The company has not disclosed any commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As such, there are no specific figures or scopes of emissions (Scope 1, 2, or 3) to report. In the absence of concrete emissions data or reduction commitments, it is important to note that SomnoMed Limited's climate strategy and initiatives remain unclear. The company does not appear to inherit emissions data from any parent or related organizations, indicating that its climate impact and commitments are independently managed. As the global focus on sustainability and carbon reduction intensifies, it will be crucial for SomnoMed Limited to establish clear climate commitments and reporting practices to align with industry standards and stakeholder expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
SomnoMed Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

